Detalhe da pesquisa
1.
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.
CA Cancer J Clin
; 72(5): 454-489, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35708940
2.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
N Engl J Med
; 390(15): 1359-1371, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38631003
3.
Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Oncologist
; 29(3): 254-262, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262444
4.
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
Lancet Oncol
; 24(5): 553-562, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37011650
5.
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Oncologist
; 28(3): e167-e170, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576430
6.
Regulation of HHLA2 expression in kidney cancer and myeloid cells.
BMC Cancer
; 23(1): 1039, 2023 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37891555
7.
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer
; 128(11): 2085-2097, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35383908
8.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med
; 378(14): 1277-1290, 2018 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29562145
9.
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Invest New Drugs
; 39(4): 1019-1027, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33507454
10.
Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
PLoS Genet
; 14(9): e1007679, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30256787
11.
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Lancet Oncol
; 21(1): 95-104, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31810797
12.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Cancer
; 126(18): 4156-4167, 2020 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32673417
13.
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Lancet
; 393(10189): 2404-2415, 2019 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31079938
14.
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
BJU Int
; 126(1): 73-82, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32233107
15.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Nature
; 515(7528): 563-7, 2014 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-25428504
16.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol
; 20(10): 1370-1385, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31427204
17.
Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma.
Cancer
; 125(23): 4148-4157, 2019 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31532565
18.
Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
Oncologist
; 24(6): 725-727, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31036769
19.
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
Oncologist
; 24(2): 202-210, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190302
20.
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Future Oncol
; 15(15): 1683-1695, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30968729